肝动脉化疗栓塞联合系统治疗肝细胞癌术后复发及腹腔淋巴结转移的临床疗效  

Clinical efficacy of hepatic artery chemoembolization combined with systemic treatment in the treatment of recurrent hepatocellular carcinoma with abdominal lymph node metastasis

作　　者：徐亮 曹广[1] 王晓东[1] 朱旭[1] 王宏伟[1] 朱向高[1] 陈辉[1] 刘鹏[1] 徐海峰[1] 郭建海[1] Xu Liang;Cao Guang;Wang Xiaodong;Zhu Xu;Wang Hongwei;Zhu Xianggao;Chen Hui;Liu Peng;Xu Haifeng;Guo Jianhai(Department of Interventional Therapy,Peking University Cancer Hospital&Institute,Beijing Institute for Cancer Research,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Educa-tion),Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所介入治疗科、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《中华消化外科杂志》2022年第S01期1-4,共4页Chinese Journal of Digestive Surgery

摘　　要：我国肝癌患者诊断时分期较晚,病史较长,5年生存率较低。国内外指南关于晚期肝癌局部治疗指征不同。肝动脉化疗栓塞的应用给晚期肝癌患者带来治疗新机会。原发性肝癌肝内复发病灶和肝外转移病灶存在肿瘤异质性,导致对免疫治疗反应存在差异,所以肝动脉化疗栓塞联合全身系统治疗,更有益于延长患者生存时间。笔者报道1例晚期肝细胞癌术后复发及腹腔淋巴结转移患者应用肝动脉化疗栓塞联合放疗及阿替利珠单克隆抗体+贝伐珠单克隆抗体治疗的临床经验。其研究结果显示:患者短期内肿瘤得到控制,取得良好的临床疗效。In China,patients with hepatocellular carcinoma(HCC)are usually with late stage and long medical history when diagnosed,resulting in a lower 5-year survival rate.For advanced HCC,guidelines from different countries have different indications for local treatment.The applica-tion of hepatic artery chemoembolization has brought new treatment opportunities to patients with advanced HCC.Due to tumor heterogeneity,the response to immunotherapy is different in patients with intrahepatic recurrent lesions and extrahepatic metastatic lesions of primary hepatic carcinoma.Therefore,hepatic artery chemoembolization combined with systemic treatment is beneficial to prolong the survival of patients.The authors introduce the clinical experience of a patient with recurrent advanced HCC combined with abdominal lymph node metastasis who was treated with hepatic artery chemoembolization combined with atezolizumab plus bevacizumab.The results show that tumor is controlled in a short period with a good clinical effect.

关 键 词：肝肿瘤 靶向治疗 肝动脉化疗栓塞 复发 淋巴结转移 

分 类 号：R735.7[医药卫生—肿瘤]